Literature DB >> 19235880

Detection of HPV types and neutralizing antibodies in Gansu province, China.

Xueling Wu1, Chuntao Zhang, Shuxian Feng, Chunyu Liu, Yanqin Li, Yongxiu Yang, Jun Gao, Hongfang Li, Shufang Meng, Liping Li, Yunzhong Zhang, Xuemei Hu, Xiaolu Wu, Lin Lin, Xun Li, Youchun Wang.   

Abstract

A total of 82 samples from patients with cervical cancer (Group 1) and 50 samples from patients with other genital diseases (Group 2) were collected in Gansu, China. All 132 samples were tested for HPV DNA with a typing kit that can detect 21 types of HPV, and also tested for neutralizing antibodies against HPV-16, -18, -58, -45, -6, and -11 using pseudovirus-based neutralization assays. The results revealed that 28% (23/82) of sera in Group 1 were positive for type-specific neutralizing antibodies with a titer range of 160-640, of which 23.2% (19/82), 2.4% (2/82), 2.4% (2/82), 1.2% (1/82), and 1.2% (1/82) were against HPV-16, -58, -6, -18, and -45, respectively. Only one serum (2%) in Group 2 was positive for neutralizing antibodies, which were against HPV-6 with a titer of 2,560. Overall, 85.4% (70/82) of samples in Group 1 were HPV DNA-positive, compared with 28% (14/50) of samples in Group 2. The seven most common types detected in Group 1 were HPV-16 (80%), HPV-52 (7.1%), HPV-66 and HPV-11 (5.7% each), and HPV-58, HPV-18, and HPV-33 (4.3% each), while the four most common types in Group 2 were HPV-16 (12%), HPV-52 and HPV-11 (6% each), and HPV-68 (4%). The concordance between HPV DNA and corresponding neutralizing antibodies was 32.9% (27/82) with a significant difference (P < 0.005). More specifically, the concordance was 42.7% (35/82) for HPV-16 in Group 1. The full-length sequences of six HPV types (HPV-16, -58, -33, -59, -11, and -68) were determined and showed 99% identities with their reported genomes. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19235880     DOI: 10.1002/jmv.21435

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  16 in total

Review 1.  Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.

Authors:  Sarah M Tiggelaar; Margaret J Lin; Raphael P Viscidi; Jia Ji; Jennifer S Smith
Journal:  J Adolesc Health       Date:  2012-02       Impact factor: 5.012

2.  Classification and nomenclature system for human Alphapapillomavirus variants: general features, nucleotide landmarks and assignment of HPV6 and HPV11 isolates to variant lineages.

Authors:  Robert D Burk; Zigui Chen; Ariana Harari; Benjamin C Smith; Boštjan J Kocjan; Polona J Maver; Mario Poljak
Journal:  Acta Dermatovenerol Alp Pannonica Adriat       Date:  2011-09

3.  Population-based human papillomavirus 16, 18, 6 and 11 DNA positivity and seropositivity in Chinese women.

Authors:  Jennifer S Smith; Adam K Lewkowitz; You-Lin Qiao; Jia Ji; Shangying Hu; Wen Chen; Rong Zhang; Kai Li Liaw; Mark Esser; Frank J Taddeo; Robert G Pretorius; Jerome L Belinson
Journal:  Int J Cancer       Date:  2012-01-27       Impact factor: 7.396

4.  Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies.

Authors:  Brenda Y Hernandez; Thien Ton; Yurii B Shvetsov; Marc T Goodman; Xuemei Zhu
Journal:  Clin Vaccine Immunol       Date:  2012-07-03

5.  Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.

Authors:  Qianqian Li; Qiang Liu; Weijing Huang; Aijing Song; Chenyan Zhao; Jiajing Wu; Youchun Wang
Journal:  Hum Vaccin Immunother       Date:  2017-03-16       Impact factor: 3.452

6.  Global Genomic Diversity of Human Papillomavirus 11 Based on 433 Isolates and 78 Complete Genome Sequences.

Authors:  Mateja M Jelen; Zigui Chen; Boštjan J Kocjan; Lea Hošnjak; Felicity J Burt; Paul K S Chan; Diego Chouhy; Catharina E Combrinck; Christine Estrade; Alison Fiander; Suzanne M Garland; Adriana A Giri; Joaquín Víctor González; Arndt Gröning; Sam Hibbitts; Tommy N M Luk; Karina Marinic; Toshihiko Matsukura; Anna Neumann; Anja Oštrbenk; Maria Alejandra Picconi; Martin Sagadin; Roland Sahli; Riaz Y Seedat; Katja Seme; Alberto Severini; Jessica L Sinchi; Jana Smahelova; Sepehr N Tabrizi; Ruth Tachezy; Sarah Tohme Faybush; Virgilijus Uloza; Ingrida Uloziene; Yong Wee Wong; Snježana Židovec Lepej; Robert D Burk; Mario Poljak
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

7.  Genomic differences in the background of different severity in juvenile-onset respiratory papillomatoses associated with human papillomavirus type 11.

Authors:  Tamás Gáll; Andrea Kis; Tímea Zsófia Tatár; Gábor Kardos; Lajos Gergely; Krisztina Szarka
Journal:  Med Microbiol Immunol       Date:  2013-05-07       Impact factor: 3.402

8.  Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer.

Authors:  Alyce A Chen; Daniëlle A M Heideman; Debby Boon; Zigui Chen; Robert D Burk; Hugo De Vuyst; Tarik Gheit; Peter J F Snijders; Massimo Tommasino; Silvia Franceschi; Gary M Clifford
Journal:  Virology       Date:  2013-11-12       Impact factor: 3.616

9.  Human papillomavirus type 6 and 11 genetic variants found in 71 oral and anogenital epithelial samples from Australia.

Authors:  Jennifer A Danielewski; Suzanne M Garland; Jenny McCloskey; Richard J Hillman; Sepehr N Tabrizi
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

10.  Development and evaluation of a pseudovirus-luciferase assay for rapid and quantitative detection of neutralizing antibodies against enterovirus 71.

Authors:  Xing Wu; Qunying Mao; Xin Yao; Pan Chen; Xiangmei Chen; Jie Shao; Fan Gao; Xiang Yu; Fengcai Zhu; Rongcheng Li; Wenhui Li; Zhenglun Liang; Junzhi Wang; Fengmin Lu
Journal:  PLoS One       Date:  2013-06-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.